

# Pharmaceutical Industry Fellowship Program 2024

In Partnership with **RUTGERS**  
Institute for Pharmaceutical  
Industry Fellowships



Seeking Gene Therapy Cures



## ABOUT ROCKET

Message from Leadership	3
Company Overview	4
Rutgers Alumni and Executive Sponsor of Program	5
Rocket, the Leader in Rare Disease Gene Therapy	6
Fellowship Mission and Overview	7
Unique Value to RPIF Fellow	8
Vision, Mission & Values	9
Our Pipeline	10
Generating Value-Based Gene Therapies	11
Patients are our North Star	12
Commitment to Diversity, Equity and Inclusion	13
Fellowship Preceptors - Industry Subject Matter Experts	14
Regulatory Affairs Fellowship Overview	16
Gene Therapy Commercial Launch Fellowship Overview	17

## RUTGERS PROGRAM

Program History	18
Key Program Features and Professional Development Series	19
Application Process, Eligibility Requirements and How to Apply	20



Dear Prospective Fellow,

On behalf of Rocket Pharmaceuticals and the Ernest Mario School of Pharmacy at Rutgers University, we would like to thank you for your interest in our fellowship program.

At Rocket, we value creative minds and unique perspectives – our goal is to help each person find their zone of genius. Our growing team is focused on elevating science, patient care, each other and humanity as we work to build our pipeline of potentially curative medicines for rare, inherited diseases.

Our passion thrives in an environment where all ideas are welcome, and every team member's opinion is valued. We truly care about making a difference and improving the lives of patients and families living with rare diseases.

We are committed to the development and training of pharmacists and physicians and understand the value that comes from working alongside and learning from industry experts. We wish you the best of luck during the recruitment process and hope you will consider the unique fellowship opportunities offered at Rocket.

Come join us in making a real impact in the lives of patients - making the impossible possible!



**Gaurav Shah, MD**  
Chief Executive Officer



**Kinnari Patel, PharmD, MBA**  
President and COO, Head of Development

Rocket Pharmaceuticals, Inc. is a clinical-stage, publicly-traded (NASDAQ: RCKT) biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket's multi-platform development approach applies the well-established lentiviral virus (LVV) and adeno-associated virus (AAV) gene therapy platforms.

Each program is intended to be transformative, enabling not only reversal of the disorder at molecular and cellular levels, but sustained relief from debilitating and potentially life-threatening symptoms. This is more than personalized medicine, it's individualized medicine with potential of providing a cure!





**Kinnari Patel, PharmD, MBA**

President and COO, Head of Development

- Proud Rutgers fellow with Pfizer and J&J from class of 2003-2005. Fellowship focused on Regulatory, clinical and safety
- Nearly 2 decades of rare disease Research & Development experience including in Regulatory Science, Pharmacovigilance, Policy and Quality Compliance; including supporting 7 drug approvals prior to joining Rocket
- Worked at leading pharma companies and involved in RPIF at Pfizer, J&J, AstraZeneca, Bristol-Myers Squibb, Novartis and Hoffmann La-Roche
- Initiated regulatory and safety fellowship programs at both BMS and AstraZeneca
- Awarded PharmaVOICE 100 of the Most Inspiring People 2018; started global “LightUpForRare” campaign
- Prominent industry thought leader recently profiled in Forbes Magazine: [Kinnari Patel Forbes Article](#)
- Education: Dual degrees of B.S. in Biology and Doctorate of Pharmacy from the USciences in Philadelphia. Executive MBA from NYU Stern School of Business with specialization in Corporate Finance, Leadership and Strategy. Graduated from the C-Suite Harvard Business School Advanced Management Program.



“My personal belief is that each person has an innate power inside themselves to make a world of difference. At Rocket, we have shaped a culture that’s focused on bringing out the best of each person.


As a minority, a woman, a pharmacist, and a first-generation immigrant, I was able to become an executive at a publicly traded company before the age of 40. At Rocket, truly anything is possible—the sky is the limit!”



Pre-eminent, ready-to-launch gene therapy pipeline in which each program is First-and Best-in-Class



Experienced management team with a history of delivering transformative and curative therapies to patients with devastating diseases



Well-capitalized and poised to elevate from a clinical-stage to a commercial-stage company



Two new products being submitted to the FDA for commercial launch anticipated in 2H2024



- To provide a once in a life hands-on experience for fellows to work on innovative, potentially curative gene therapy programs with multiple new product filings and commercial launches in 2024-2025
- To create a unique fellowship program that fosters culture of trust, curiosity, generosity and elevate in a mission to find cures for devastating rare diseases
- To be at the forefront of innovation while working alongside motivated team members bringing best-in-class curative gene therapies to patients with sense of urgency and care
- Structured program designed to provide hands-on training and guidance from industry and global gene-therapy experts
- Establish a strong foundation to allow fellows to build a successful life-long career within drug development industry and to be competitively sought after
- Develop key talent and the future leaders of industry to help drive the demand for pharmacists in the future of drug development



**Latika Hickey, PharmD**

(Rutgers PharmD Post-doc fellow Bristol-Myers Squibb 2002-03)

Unique professional and leadership opportunities including:

- Be at the forefront of innovation and regulatory policy at a rapidly-growing company
- Learn from internal and external experts and thought leaders in the field of gene therapy
- High visibility and exposure to senior management
- Hands on cross-functional experience

Gain both breadth and depth of experience in short period of time, while making a real difference for patients

Be a part of the regulatory approval process and launch of some of the most complex and innovative therapies ever developed

Opportunity to accelerate your career path in the industry and make an impact on a global scale – establish your own footprint in a hot sector of drug development

Establish a strong foundation that supports career advancement at Rocket and other companies



"Every day I work at Rocket Pharma, I feel a sense of gratitude...towards my colleagues who always try to help me succeed...towards the patients we serve...towards the scientists who are driving toward unprecedented medical advancements. Here, we are a community with shared values of integrity, curiosity, and a relentless focus on solving problems."



## Values



Curiosity



Trust



Elevate



Generosity

## Mission

To develop **first-in-class** and **best-in-class curative gene therapies** for patients with devastating diseases

# Strong Science, Carefully-selected Assets and Smart Execution: 6 Disclosed programs with compelling clinical and/or pre-clinical proof of concept


## Criteria used to select programs



First-, best- and/or only-in-class




On-target MOA; clear endpoints



Sizeable market to maximize patient impact

6+ programs with 2 programs fast approaching regulatory filing and launch



AAV, adeno-associated virus; ATMP, advanced therapy medicinal product; BLA, Biologics License Application; LV, lentiviral vector; MAA, Marketing Authorisation Application; MOA, mechanism of action; PRIME, PRiority MEDicines; RMAT, regenerative medicine advanced therapy. PKP2: plakophilin 2; ACM: Arrhythmogenic Cardiomyopathy; BAG3: BLC2-associated athanogene 3 DCM: Dilated Cardiomyopathy  
Data on file. Rocket Pharmaceuticals. 2023.

Multi-platform,  
first-and-best in-class  
approach to treating  
**complex and life-  
threatening childhood  
disorders**

- Late-stage science and innovation
- Collaboration and expertise
- Strong capabilities and financials

**WORLD-CLASS**

scientific experts and partners learning from and collaborating with patient communities

Well capitalized to develop full pipeline of assets with

**\$307M**

in cash and equivalents; sufficient to fund operations into 1H 2025

**~100,000 SQ FT**

US-based in-house facility dedicated to AAV cGMP manufacturing

Leadership team with proven track record of

**20+** drug approvals and launches

At Rocket we're truly committed to keeping patients in mind throughout everything we do, from designing first in human clinical trials so that they're as accessible as possible to patients and their families, to organizing patient-centered events like our annual Rare Disease Day.

Rocket's Rare Disease Day celebration on February 28, 2022 brought together over 250 members of the rare disease community, both in person at the NASDAQ Tower in Times Square and virtually.

Our mission is to seek gene therapy cures for people living with rare diseases, who are our North Star. In celebration of Rare Disease Day 2023, Rocket held an event at the Make-A-Wish New Jersey Samuel & Josephine Plumeri Wishing Place in Monroe Township, NJ. Resembling a fairy tale castle and dedicated to granting the wishes of children with critical illnesses, the Make-A-Wish venue provided a meaningful backdrop to the event that brought together more than 200 people and featured inspirational stories from the global rare disease community.



Joining the Rocket team means joining the Rocket family and becoming an integrated member of our community. We believe in having an open environment where all ideas are welcome, and every team member's opinion is valued. One mindset that remains constant among all Rocket employees, however, is our commitment to the work we do beyond just our time in the office. We truly care about making a difference and improving the lives of patients and families living with rare diseases.

Rocket is comprised of and celebrates diversity in age, gender, experiences, educational background and thinking.

Everyone brings his or her unique perspective to the table. We have built our company like a puzzle – each of our differences become part of our whole, a team that can move mountains.





**Ed Trzaska, MBA / Senior Director, Business Insights & Analytics**

- 20+ years of pharmaceutical and biotech Insights & Analytics experience, including 10+ years of functional leadership of large teams (market research, advanced analytics, forecasting, and competitive intelligence)
- 8 years managing Fellowship and Leadership Development programs for PharmDs and MBAs
- 10+ years of rare disease experience, 12 successful product launches, including \$1B+ rare disease treatment
- Rutgers University Alumni – Chemical Engineering (BS) and Pharmaceutical Management and Marketing (MBA)
- Developed numerous innovative techniques for patient finding models, machine learning predictive algorithms, and behavioral sciences/heuristics applications
- Preceptor for Gene Therapy Commercial Launch Fellowship



“We will provide a world-class commercial experience that will shape and accelerate careers. Our fellows will be launching some of the most complex and innovative therapies ever developed and have broad exposure to Rocket’s executive leadership.”



**Sanchali Kasbekar, PharmD / Senior Director, Regulatory Affairs**

- 10+ years of rare disease Research & Development
- Worked at leading pharma companies and involved in RPIF at AstraZeneca and Bristol-Myers Squibb
- Serve as RPIF mentor to over 10 fellows across various functional areas
- Rutgers Fellowship Alumni – 2-yr BMS Global Regulatory & Safety Sciences
- Preceptor for Regulatory Affairs Fellowship and Director of Rutgers Fellowship Program at Rocket



"The best career decision I made was to join Rocket. It is a once in a lifetime opportunity -- the culture, the people, the opportunities. You are at the forefront of innovation where your individual contributions transform the lives of patients. Here, your potential is limitless."

The fellow will be exposed to an overview of global regulatory affairs including regulatory CMC, advertising & promotion and regulatory strategy by direct hands-on experience, with opportunities for fellows to work with cross-functional team to provide strategic input to support development on therapies across various stages of drug development.

- Exposure to and knowledge of global regulations and how to integrate them into the overall global strategy (clinical and CMC) supporting the development and approval
- Planning and preparation for health authority interactions
- Identification and assessment of regulatory risks
- Support the planning and preparation of global clinical and CMC regulatory documents
- Support global regulatory submissions eg INDs/CTAs, BLAs, MAAs, designations
- Perform competitive regulatory intelligence
- Closely work with cross-functional team members and management to identify strategies that meet both regulatory requirements and commercial objectives
- Work closely with regulatory policy and agencies (FDA and EMA) to be at the forefront of changes in the regulatory environment
- Drive policy changes – ground-breaking drug development






The fellow will be exposed to the commercial business via direct hands-on experience, with opportunities to work on gene therapy launches across numerous programs and both LVV and AAV platforms, as well as exposure to the various functional areas and geographic markets.

The fellow will be trained as a commercial launch professional including the following activities:

- Support the global launches for multiple programs in the US and EU
- Work with various business partners across all functional areas at Rocket
- Learn about launch plans, timelines, strategies, goals, and cross-functional dependencies critical for success
- Begin with a rotation on the Insights & Analytics team learning about market research, forecasting, advanced analytics, and competitive intelligence (how to apply to ultra rare diseases and the unique features of LVV and AAV gene therapies)
- Continue the fellowship with rotations in marketing, value & access, or medical affairs
- Develop skills such as relationship building, effective communication, and influencing
- Assess and select project vendors, manage project timelines, and develop final deliverables
- Present actionable project findings to business partners and senior leadership





### Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy  
Rutgers, The State University of New Jersey



**Joseph A. Barone,**  
Pharm.D., F.C.C.P.  
Dean and Professor II  
Ernest Mario School of  
Pharmacy  
Rutgers University



**Carolyn Seyss,**  
Pharm.D., RUCIF  
Fellowship Director  
Institute for Pharmaceutical Industry  
Fellowships  
Ernest Mario School of Pharmacy



**Michael Toscani,**  
Pharm.D.  
Research Professor,  
Fellowship Director Emeritus  
Institute for Pharmaceutical  
Industry Fellowships

#### Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the *Institute for Pharmaceutical Industry Fellowships* to enhance and promote the role of pharmacists in industry through the RPIF Program.

The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**. Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.



Connect with us on social  
media: @RutgersFellow



### Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTERs** the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

- F** **Family of Leading Companies** – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.
- O** **Outstanding Alumni Track Record** – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
- S** **Strong Network** — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
- T** **Trusted and Proven Since 1984** — the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.
- E** **Enhanced Career Development** – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
- R** **Rigorous Academic Component** – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The [Ernest Mario School of Pharmacy \(EMSOP\)](#) is part of Rutgers Biomedical and Health Sciences (RBHS), the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

### Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.



Connect with us on social  
media: @RutgersFellow



### Application Process and Eligibility Requirements:

Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

### How to Apply:

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 6, 2023 by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

### **Your Letter of Intent & Letters of Recommendation should be addressed to:**

Joseph A. Barone, Pharm.D., F.C.C.P.  
Dean and Professor II  
Ernest Mario School of Pharmacy  
Rutgers, The State University of New Jersey  
160 Frelinghuysen Road  
Piscataway, NJ 08854-8020

### Alliance of Industry Fellowship Associates Fellowship Offers

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, AIFA exists to promote a common aspect of each of our program's cultures by supporting a consensus first offer date of December 13, 2023 for all fellowship candidates.

We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.

Required Items	Submit by
Application with short-answer questions	October 13th
Letter of Intent (LOI)	October 13th
Curriculum Vitae (CV)	October 13th
Letters of Recommendation (LORs)	December 1st



# AIFA

Alliance of Industry Fellowship Associates



Connect with us on social  
media: @RutgersFellow